Soteria Biotherapeutics

Soteria Biotherapeutics

Soteria Biotherapeutics is a biotechnology company developing cancer immunotherapies.

Soteria Biotherapeutics is a biotechnology company developing cancer immunotherapies that is headquartered in San Francisco, California and was founded in 2018 by Alexander Martinko and Zachary Hill.

Soteria Biotherapeutics is developing t-cells that are conditioned to engage antibodies to treat solid tumor cancers. Their platform T-LITETM, offers small molecule-dependent activation of bispecific antibody therapies. The platform is designed to enable treatments through pulsatile activity, and reduce side effects.

The platform incorporates a small molecule-controlled switch to carry out its use and T-cell cytotoxic activity. The platform creates the activity of immunomodulatory therapeutics such as bi-specific T-Cell engagers, and CAR T-cells. Soteria Biotherapeutics offers services in order to develop their protein switches.

Timeline

People

Name
Role
LinkedIn

Alexander Martinko

Co-Founder

Zachary Hill

Co-Founder

Further reading

Title
Author
Link
Type
Date

Soteria Biotherapeutics Company Profile: Valuation & Investors | PitchBook

Web

Soteria Biotherapeutics Company Profile: Valuation & Investors | PitchBook

Web

Documentaries, videos and podcasts

Title
Date
Link

Soteria Therapeutics Pitch Example | UCSF Entrepreneurship Center Startup 101

May 15, 2018

Companies

Company
CEO
Location
Products/Services

Soteria Biotherapeutics

San Francisco, California, United States

Biotherapeutics

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.